NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6750.50 -37.00 (-0.55%)

Near 52W High of ₹7071.50

252.4K NSE+BSE Volume

NSE 23 Jun, 2026 2:20 PM (IST)

179,204.6

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Dividend

Divi's Laboratories has an upcoming dividend of ₹30.000 per share due on 24 Jul 2026 See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

28 May 2026

6750.50

-0.55%

Valuation

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 15.3% / 20% / 18.2% for the period of FY26-FY28.

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

25 May 2026

6750.50

-0.55%

Divi's Laboratories (DIVI IN) Q4FY26 Result Update EBITDA miss; Peptide opportunities key for growth ACCUMULATE

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY26 EBITDA missed our estimates due to lower gross margin. Revenues were largely aided by CS segment and currency tailwind. Mgmt indicated inventory levels may increase further in Q1FY27E to ensure uninterrupted operations. We expect stable margins in FY27 and expect revenue to accelerate from FY28 as commencement of some CDMO and contrast media contracts along with peptide revenue scale up. Our FY27E/FY28E EPS estimates stand cut by 2-4%. We expect 19% EBITDA and PAT CAGR over FY26-28E. At CMP, stock is trading at 52x...

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

24 May 2026

6750.50

-0.55%

Divi's Labs (HOLD): Margin headwinds to persist in near term

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 3.4%/10%/1 below our estimates. EBITDA Margin was reported 235 bps below our estimates at 33%

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

06 Apr 2026

6750.50

-0.55%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The outlook remains positive, supported by Divi's strong positioning in custom synthesis and a diversified pipeline, with management highlighting active engagement with global innovator customers and multiple projects progressing through development and validation. Ongoing capacity additions along with a focus on disciplined execution and supply reliability are expected to support future growth, while the nutraceuticals business continues to provide healthy momentum and diversification. The company has also completed construction of a dedicated peptide facility, strengthening its capabilities in this fast-evolving segment, and...

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

20 Nov 2025

6750.50

-0.55%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

10 Nov 2025

6750.50

-0.55%

Divi's Labs (HOLD): Key molecule LOE to risk upside growth in Custom Synthesis

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 3%/9%/11% above estimates. EBITDA margin reported 170 bps above estimates.

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Divi's Laboratories Ltd.

10 Nov 2025

6750.50

-0.55%

Divi's Laboratories (DIVI IN) Q2FY26 Result Update Peptides...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

09 Nov 2025

6750.50

-0.55%

Generics continue to drag growth, CS outlook unchanged

Sell: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

08 Nov 2025

6750.50

-0.55%

Operating leverage and CS strength support margins

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered better-than-expected performance in 2Q with a 4%/10%/10% beat on revenue/EBITDA/PAT.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

10 Sep 2025

6750.50

-0.55%

DIVI' S LAB

Sell: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The company's outlook remains positive due to growth drivers such as increased traction from global innovators, a healthy pipeline of RFPs, expansion of scientific and technological capabilities, and steady growth in the nutraceutical business. Management highlighted persistent pricing pressures in generics and higher cost escalation compared to custom synthesis, weighing on margins. Regulatory delays of 12-24 months for peptides, contrast media, and Kakinada approvals restricted near term revenue conversion. Divi's also faces the risk of losing business related to...

Number of FII/FPI investors decreased from 868 to 842 in Mar 2026 qtr

Is Divi's Laboratories Ltd. worth buying?

757 Votes:

Buy 78.2%

Sell 14.93%

Hold 6.87%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf